THE TGA has approved Sanofi’s
Jevtana (cabazitaxel) in
combination with prednisone or
prednisolone for the treatment of
patients with hormone refractory
metastatic prostate cancer
previously treated with a docetaxel
containing regimen.
Jevtana is the first approved
agent to significantly extend overall
survival in patients whose disease
has progressed during or after
docetaxel-containing treatment.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Dec 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Dec 11
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.